Fig. 8: Correlations of ECM1a, ECM1b, integrin αX, integrin β2, and hnRNPLL levels with cancer patient survival. | Nature Communications

Fig. 8: Correlations of ECM1a, ECM1b, integrin αX, integrin β2, and hnRNPLL levels with cancer patient survival.

From: Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness

Fig. 8

Design of antibodies recognizing ECM1 subtypes (a) and detection of ECM1 subtypes in HeyA8 cells expressing ECM1 shRNA and further transfected with vector (A8i-V), ECM1a (A8i-A), ECM1b (A8i-B), or ECM1c (A8i-C) cDNAs by WB analysis with specific antibodies (b). c–i Representative images from the TMA. IHC showed different levels of ECM1a (c, detected with the ECM1-01 antibody), ECM1a or ECM1b (d, detected with the ECM1-02 antibody), ECM1c (e, detected with the ECM1-03 antibody), integrin αX (f), integrin β2 (g), hnRNPLL (h), and ABCG1 (i); bars = 400 or 100 μm indicating different magnifications of the tissues. j A TMA consisting of 150 high-grade serous OC tissues and 30 normal ovarian tissues was stained by IHC for analysis of ECM1 subtypes, integrin αX, integrin β2, hnRNPLL, and ABCG1 expression. The level of each protein was classified as high or low expression. Survival analysis conducted with Kaplan–Meier plots showed that poor OS and DFS were associated with high expression of ECM1a, integrin αX, integrin β2, ABCG1, and hnRNPLL, whereas favorable OS and DFS were associated with high expression of ECM1b. Two-tailed t-test was used for survival analyses.

Back to article page